Dr. Drucker is a dermatologist and researcher focusing on epidemiology and evidenced-based treatment of skin disease. Through his research, Dr. Drucker aims to improve the lives of people with or at risk for inflammatory and neoplastic skin disease by evaluating risk factors, comorbidities, health service utilization and evidence-based treatments.
Dr. Drucker’s research is currently helping patients and clinicians navigate new treatments available for eczema (atopic dermatitis). This is an exciting time for individuals with eczema as there are many new treatments being studied to help those with more severe disease, where topical treatments are not enough. Dr. Drucker leads an international team conducting a living network meta-analysis of systemic immunomodulatory treatments for eczema. Through EczemaTherapies.com, this team is committed to providing the most up-to-date information on treatments for eczema to share with patients and clinicians.
Dr. Drucker is also focused on the safety of medications used in dermatology, particularly in older adults. He is currently studying potential adverse effects of topical and oral steroids used for people with eczema and is conducting a Canadian Institutes of Health Research (CIHR) funded study to evaluate the safety of biologic medications for older adults with psoriasis and psoriatic arthritis.
ScM, Clinical and Translational Research, Brown University
M.D., Queen’s University
- International Society for Atopic Dermatitis Rajka Medal (2022)
- American Academy of Dermatology Young Investigator award (2020)
- Canadian Dermatology Association Research Award in Dermatology (2020)
- Evidence-based treatment of skin disease
- Medication safety